Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea's Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company's pipeline through global partnering and commercialization efforts.

Company profile
Ticker
NAVB
Exchange
Website
CEO
Jed Latkin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NEOPROBE CORP
SEC CIK
Corporate docs
Subsidiaries
Navidea Biopharmaceuticals Europe Limited • Navidea Biopharmaceuticals Limited • Macrophage Therapeutics, Inc. ...
IRS number
311080091
NAVB stock data
News
Navidea Biopharmaceutical Q2 EPS $(0.10) Down From $(0.09) YoY, Sales $57.00K Down From $261.05K YoY
15 Aug 22
Navidea Biopharmaceuticals Announces Publication Of Study Examining Use Of Tc99m Tilmanocept For Lymphatic Mapping And Sentinel Lymph Node Biopsy In Melanoma And Oral Cancer In Australia
1 Aug 22
Navidea Biopharmaceuticals Highlights Publication Of Study Examining Tc99m Tilmanocept Imaging Of Arterial Inflammation In People With HIV
25 Jul 22
Press releases
Navidea Biopharmaceuticals Reports Second Quarter 2022 Financial Results
15 Aug 22
Navidea Biopharmaceuticals Announces Commencement of Rights Offering Subscription Period and Updated Terms of its Previously Announced Rights Offering
4 Aug 22
Navidea Biopharmaceuticals Announces Publication of Study Examining Use of Tc99m Tilmanocept for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Melanoma and Oral Cancer in Australia
1 Aug 22
Navidea Biopharmaceuticals Reminds Investors of Today's Deadline to be a Shareholder of Record for the Previously Announced Rights Offering
1 Aug 22
Navidea Biopharmaceuticals Announces Publication of Study Examining Tc99m Tilmanocept Imaging of Arterial Inflammation in People with HIV
25 Jul 22
Investment data
Securities sold
Number of investors
Calendar
15 Aug 22
16 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 328.01K | 328.01K | 328.01K | 328.01K | 328.01K | 328.01K |
Cash burn (monthly) | 296.37K | 565.51K | 974.2K | 997.99K | 713.1K | 786.35K |
Cash used (since last report) | 465.35K | 887.95K | 1.53M | 1.57M | 1.12M | 1.23M |
Cash remaining | -137.34K | -559.94K | -1.2M | -1.24M | -791.69K | -906.71K |
Runway (months of cash) | -0.5 | -1.0 | -1.2 | -1.2 | -1.1 | -1.2 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Jul 22 | Amit Bhalla | Common Stock | Grant | Acquire A | No | No | 0 | 2,500 | 0 | 63,068 |
31 Jul 22 | Alexander L Cappello | Common Stock | Grant | Acquire A | No | No | 0 | 2,500 | 0 | 58,977 |
31 Jul 22 | Scott John K Jr. | Common Stock | Grant | Acquire A | No | No | 0 | 2,500 | 0 | 8,100,895 |
31 Jul 22 | Malcolm G Witter | Common Stock | Grant | Acquire A | No | No | 0 | 2,500 | 0 | 156,388 |
30 Jun 22 | Amit Bhalla | Common Stock | Grant | Acquire A | No | No | 0 | 2,500 | 0 | 60,568 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
API, appraisal, arrival, bisphosphonate, clawback, destination, Dis, ingredient, installment, Jul, Junior, NDA, NN, online, point, satisfaction, shipment, shipping, sponte, sua, Summit, Tc, technetium, unregistered, warrant, wire
Removed:
Cerveau, exclusive, inception, relating, Singapore
Financial reports
Current reports
8-K
Navidea Biopharmaceuticals Reports First Quarter 2022 Financial Results
12 May 22
8-K
Other Events
20 Apr 22
8-K
Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American
12 Apr 22
8-K
Navidea Biopharmaceuticals Announces New Senior Regulatory Consultant and Return of Former Director of Regulatory Affairs
7 Apr 22
8-K
Navidea Biopharmaceuticals Reports Fourth Quarter 2021 Financial Results
23 Mar 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Feb 22
8-K
Navidea Biopharmaceuticals Terminates Stock Purchase Agreement
16 Dec 21
8-K
Other Events
13 Dec 21
8-K
Navidea Biopharmaceuticals Announces Business Update Call and Changes to Board of Directors Composition
9 Dec 21
8-K
Departure of Directors or Certain Officers
25 Nov 21
Registration and prospectus
424B4
Prospectus supplement with pricing info
4 Aug 22
FWP
Free writing prospectus
22 Jul 22
S-1/A
IPO registration (amended)
1 Jul 22
POS AM
Prospectus update (post-effective amendment)
18 May 22
POS AM
Prospectus update (post-effective amendment)
18 May 22
POS AM
Prospectus update (post-effective amendment)
18 May 22
POS AM
Prospectus update (post-effective amendment)
18 May 22
8-A12B
Registration of securities on exchange
12 Apr 22
Other
EFFECT
Notice of effectiveness
4 Aug 22
EFFECT
Notice of effectiveness
25 May 22
EFFECT
Notice of effectiveness
25 May 22
EFFECT
Notice of effectiveness
25 May 22
EFFECT
Notice of effectiveness
25 May 22
CERT
Certification of approval for exchange listing
13 Apr 22
EFFECT
Notice of effectiveness
25 May 21
CORRESP
Correspondence with SEC
19 May 21
UPLOAD
Letter from SEC
18 May 21
EFFECT
Notice of effectiveness
17 Feb 21
Ownership
4
NAVIDEA BIOPHARMACEUTICALS / Malcolm G Witter ownership change
1 Aug 22
4
NAVIDEA BIOPHARMACEUTICALS / John K Jr. Scott ownership change
1 Aug 22
4
NAVIDEA BIOPHARMACEUTICALS / ALEXANDER L CAPPELLO ownership change
1 Aug 22
4
NAVIDEA BIOPHARMACEUTICALS / Amit Bhalla ownership change
1 Aug 22
4
NAVIDEA BIOPHARMACEUTICALS / Malcolm G Witter ownership change
5 Jul 22
4
NAVIDEA BIOPHARMACEUTICALS / John K Jr. Scott ownership change
5 Jul 22
4
NAVIDEA BIOPHARMACEUTICALS / ALEXANDER L CAPPELLO ownership change
5 Jul 22
4
NAVIDEA BIOPHARMACEUTICALS / Amit Bhalla ownership change
5 Jul 22
4
NAVIDEA BIOPHARMACEUTICALS / Malcolm G Witter ownership change
1 Jun 22
4
NAVIDEA BIOPHARMACEUTICALS / John K Jr. Scott ownership change
1 Jun 22
Patents
Utility
Dual Balloon Catheter and Related Methods for Treatment of Heart Failure
30 Jun 22
A dual balloon catheter having two independently inflatable balloons that provides complete or intermittent synchronous occlusion of blood vessels (such as the contralateral iliac veins, for example) via the balloons, which can be used for the purpose of decreasing the pressure in the inferior vena cava, which results in decongestion of the kidneys, liver/splanchnic compartment, lymphatic system, and the heart.
Utility
Synthesis of Uniformly Defined Molecular Weight Mannosylated Dextrans and Derivatives Thereof
13 Jan 22
Disclosed herein is method for conjugating a metal chelating agent to a functionalized dextran by reacting a chelator with an aminated dextran backbone, where the chelator comprises a one, and only one, derivatized carboxylic acid group to form a chelator-dextran complex.
Utility
Compounds and Methods for Diagnosis and Treatment of Viral Infections
4 Nov 21
Compositions and methods of using these compositions that can include a targeting moiety and a therapeutic agent are described herein.
Utility
Compositions and Related Methods for Blocking Off-target Localization of Mannosylated Dextrans and Other CD206 Ligands
20 May 21
Disclosed is a method for increase target specificity of a mannosylated dextran therapeutic or diagnostic compound by administering at least a blocking composition comprising a backbone and one or more CD206 targeting moieties attached thereto; administering an effective amount of the mannosylated dextran therapeutic or diagnostic compound comprising a dextran backbone and one or more CD206 targeting moieties and one or more therapeutic agents attached thereto.
Utility
Compounds and methods for diagnosis and treatment of viral infections
18 May 21
Compositions and methods of using these compositions that can include a targeting moiety and a therapeutic agent are described herein.
Transcripts
2022 Q1
Earnings call transcript
13 May 22
2021 Q4
Earnings call transcript
24 Mar 22
2021 Q3
Earnings call transcript
11 Nov 21
2021 Q2
Earnings call transcript
12 Aug 21
2021 Q1
Earnings call transcript
12 May 21
2020 Q4
Earnings call transcript
25 Mar 21
2020 Q3
Earnings call transcript
12 Nov 20
2020 Q2
Earnings call transcript
14 Aug 20
2020 Q1
Earnings call transcript
14 May 20
2019 Q4
Earnings call transcript
12 Mar 20
Reddit threads
Daily Discussion Thread - August 16th, 2022
16 Aug 22
Daily Discussion Thread - August 10th, 2022
10 Aug 22
Daily Discussion Thread - August 9th, 2022
9 Aug 22
Worth holding? Or sell and move to index funds and ETFs.
15 Jun 22
Daily Discussion Thread - May 12th, 2022
12 May 22
Daily Discussion Thread - May 11th, 2022
11 May 22
Good morning! 🌞 #premarket #watchlist 04/19 $TBLT -earnings, $STSS -insider buying, $NAVB -Regulatory Approval of Lymphoaim in India, $AXSM - received and agreed Postmarketing Requirements proposed by the FDA for NDA, $CMPI -buyout... Also check afterhours runners and low float stocks in my app!
19 Apr 22
Pre-market April 19th
19 Apr 22
Pre-market summary - April 13th
13 Apr 22
Daily Discussion Thread - March 23rd, 2022
23 Mar 22